Relmada Therapeutics (RLMD) Stock Price, News & Analysis

Company Overview

Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings. In parallel, the company is advancing additional pipeline programs targeting neuropathic pain, including diabetic neuropathy and chemotherapy-induced peripheral neuropathy. Relmada collaborates with academic centers and contract research organizations to conduct multi-center trials across North America and Europe.

Headquartered in New York, Relmada Therapeutics was incorporated in Delaware and maintains its research operations in the United States. The company is led by a management team with extensive experience in biopharmaceutical development, regulatory strategy and commercial planning. Relmada’s common stock is listed on the NASDAQ under the symbol RLMD.

Key Stats

• Today's Range: $2.06 to $2.27
• 50-Day Range: $0.56 to $2.66
• 52-Week Range: $0.24 to $3.98
• Volume: 327,401 shs
• Average Volume: 1.16 million shs
• Market Capitalization: $72.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Reduce

Relmada Therapeutics Stock Analysis - MarketRank™

Relmada Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 602nd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Relmada Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.

Downside Risk

Relmada Therapeutics has a consensus price target of $1.00, representing about 55.7% downside from its current price of $2.26.

Amount of Analyst Coverage

Relmada Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Relmada Therapeutics are expected to grow in the coming year, from ($2.73) to ($0.63) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Relmada Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Relmada Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Relmada Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.14% of the outstanding shares of Relmada Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Relmada Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Relmada Therapeutics has recently increased by 27.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Relmada Therapeutics does not currently pay a dividend.

Dividend Growth

Relmada Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.45

Percentage of Shares Shorted

2.14% of the outstanding shares of Relmada Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Relmada Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Relmada Therapeutics has recently increased by 27.63%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Relmada Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for RLMD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

6 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Relmada Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.70% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RLMD Stock Analysis - Frequently Asked Questions

How have RLMD shares performed this year?

Relmada Therapeutics' stock was trading at $0.52 at the beginning of the year. Since then, RLMD stock has increased by 333.7% and is now trading at $2.2550.

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.05.
Read the conference call transcript.

How do I buy shares of Relmada Therapeutics?

Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Relmada Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Relmada Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), ServiceNow (NOW), GE Aerospace (GE) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/09/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RLMD
• CIK: 1553643
• Web: www.relmada.com
• Phone: (786) 629-1376
• Fax: N/A
• Employees: 10
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Relmada Therapeutics: $1.00
• High Price Target: $1.00
• Low Price Target: $1.00
• Potential Upside/Downside: -53.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -223.17%
• Return on Assets: -180.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.11
• Quick Ratio: 4.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.18 per share
• Price / Book: 1.83

Miscellaneous

• Outstanding Shares: 33,190,000
• Free Float: 26,321,000
• Market Cap: $71.69 million
• Optionable: Optionable
• Beta: 0.91